Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The human milk oligosaccharide 3′sialyllactose reduces low-grade inflammation and atherosclerosis development in mice
Ariane R. Pessentheiner, … , Lars Bode, Philip L.S.M. Gordts
Ariane R. Pessentheiner, … , Lars Bode, Philip L.S.M. Gordts
Published September 26, 2024
Citation Information: JCI Insight. 2024;9(21):e181329. https://doi.org/10.1172/jci.insight.181329.
View: Text | PDF
Research Article Cell biology Inflammation

The human milk oligosaccharide 3′sialyllactose reduces low-grade inflammation and atherosclerosis development in mice

  • Text
  • PDF
Abstract

Macrophages contribute to the induction and resolution of inflammation and play a central role in chronic low-grade inflammation in cardiovascular diseases caused by atherosclerosis. Human milk oligosaccharides (HMOs) are complex unconjugated glycans unique to human milk that benefit infant health and act as innate immune modulators. Here, we identify the HMO 3′sialyllactose (3′SL) as a natural inhibitor of TLR4-induced low-grade inflammation in macrophages and endothelium. Transcriptome analysis in macrophages revealed that 3′SL attenuates mRNA levels of a selected set of inflammatory genes and promotes the activity of liver X receptor (LXR) and sterol regulatory element binding protein-1 (SREBP1). These acute antiinflammatory effects of 3′SL were associated with reduced histone H3K27 acetylation at a subset of LPS-inducible enhancers distinguished by preferential enrichment for CCCTC-binding factor (CTCF), IFN regulatory factor 2 (IRF2), B cell lymphoma 6 (BCL6), and other transcription factor recognition motifs. In a murine atherosclerosis model, both s.c. and oral administration of 3′SL significantly reduced atherosclerosis development and the associated inflammation. This study provides evidence that 3′SL attenuates inflammation by a transcriptional mechanism to reduce atherosclerosis development in the context of cardiovascular disease.

Authors

Ariane R. Pessentheiner, Nathanael J. Spann, Chloe A. Autran, Tae Gyu Oh, Kaare V. Grunddal, Joanna K.C. Coker, Chelsea D. Painter, Bastian Ramms, Austin W.T. Chiang, Chen-Yi Wang, Jason Hsiao, Yiwen Wang, Anthony Quach, Laela M. Booshehri, Alexandra Hammond, Chiara Tognaccini, Joanna Latasiewicz, Lisa Willemsen, Karsten Zengler, Menno P.J. de Winther, Hal M. Hoffman, Martin Philpott, Adam P. Cribbs, Udo Oppermann, Nathan E. Lewis, Joseph L. Witztum, Ruth Yu, Annette R. Atkins, Michael Downes, Ron M. Evans, Christopher K. Glass, Lars Bode, Philip L.S.M. Gordts

×

Figure 5

3′SL mediates reprogramming of the NF-κB enhancer landscape activity to attenuate inflammation.

Options: View larger image (or click on image) Download as PowerPoint
3′SL mediates reprogramming of the NF-κB enhancer landscape activity to ...
(A) De novo motif analysis of 3′SL + LPS repressed enhancers (versus LPS) using a GC-matched genomic background. (B) Venn diagram of 3′SL-LPS repressed genes compared with LPS induced enhancers associated with NF-κB/p65 bound loci. (C) IPA analysis of upstream regulators of differentially expressed genes (|Z score| > ± 2). (D) Distribution of H3K27ac tag densities in the vicinity of genomic regions cobound by NF-κB/p65 in BMDMs treated with indicated stimuli for 6 hours. (E) Distribution of p300 tag densities in the vicinity of genomic regions cobound by NF-κB/p65 in BMDMs treated with indicated stimuli for 6 hours. (F and G) UCSC genome browser images illustrating normalized tag counts for H3K27ac at Il1a, Il6,and Cxcl10 target loci together with mapped ATAC-Seq tags. (H) De novo motif analysis of 3′SL + LPS repressed enhancers (versus LPS) using all LPS-induced ATAC-Seq peaks as a background. Unpaired 2-tailed Student’s t test. *P < 0.05; **P < 0.01. Data represent mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts